News Reader.info

ABSTRACT Although antithyroid drug (ATD)-induced agranulocytosis is a significant concern, its risks associated with long-term use and re-administration are not fully elucidated. Therefore,

we performed this study to determine the incidence of ATD-induced leukopenia and G-CSF administration using administrative claims database. Retrospective cohort study. This study was

performed using the DeSC Japanese administrative claims database. A total of 12,491 patients with newly diagnosed Graves’ disease (GD) who received methimazole or propylthiouracil between

April 2014, and February 2021 among 3.44 million patients in the database were included in the study. We measured the six-year incidence of leukopenia and granulocyte colony-stimulating

factor (G-CSF) administration. The incidence of leukopenia and G-CSF administration was 1.34% (168 patients) and 0.30% (38 patients), respectively. Leukopenia had a dose-dependent and

biphasic incidence. The incidence of leukopenia and G-CSF administration was 37.2 (0.7%) and 8.0 (0.2%) per 1000 person-years during the first 72 days of ATD initiation, whereas it was 3.1

and 0.7 per 1000 person-years during the subsequent 6 years, respectively. The incidence of both outcomes was comparable between first administration and re-administration of ATD. The

incidence of ATD-induced leukopenia and G-CSF administration was high in the first 72 days, with a reduced risk for at least 6 years thereafter. The incidence was similar between first

administration and re-administration. ATD, a standard therapy, is often administered for a long period; therefore, our findings can guide the treatment of GD. SIMILAR CONTENT BEING VIEWED BY

OTHERS TREATMENT OUTCOMES AND ADHERENCE TO TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN TWO ETHIOPIAN TEACHING HOSPITALS: A RETROSPECTIVE COHORT STUDY Article Open access 24 May

2024 DECIPHERING TREATMENT PATTERNS IN NON-SEVERE/MODERATE APLASTIC ANEMIA: AN INTERNATIONAL OBSERVATIONAL STUDY Article Open access 04 October 2023 IBRUTINIB IN COMBINATION WITH RITUXIMAB

IS HIGHLY EFFECTIVE IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH STEROID REFRACTORY AND RELAPSED AUTOIMMUNE CYTOPENIAS Article 18 May 2023 INTRODUCTION Antithyroid drugs (ATD)

are the standard therapy for Graves’ disease (GD) worldwide. The European Thyroid Association and Japan Thyroid Association guidelines recommend ATD, particularly methimazole (MMI), as the

initial therapy for GD. MMI can be used for 12–18 months and discontinued if TSH and TSH receptor antibody (TRAb) levels are within normal ranges. If TRAb levels remain elevated, radioactive

iodine (RAI) therapy or surgery is recommended1. In selected cases, long-term treatment with ATD is considered because it may increase the chance of remission2. In the United States, RAI

therapy is the traditional approach, although recently, there is an increasing trend in ATD use and decrease in RAI use3. ATD-induced agranulocytosis is a rare but serious and potentially

life-threatening condition. In severe cases, granulocyte colony-stimulating factor (G-CSF) administration is recommended to hasten bone marrow recovery4,5. The reported incidence of

agranulocytosis is 0.1–0.5%; this condition generally develops within 90 days of therapy initiation5,6,7,8. The exact incidence of late-stage agranulocytosis remains unclear, despite some

reports7,8,9,10. In addition, these reports include single-center or multicenter studies conducted in specialized hospitals and those from pharmaceutical companies7; there is a lack of

epidemiological data from general clinical cohort studies with a low risk of bias. Furthermore, the risks of long-term ATD administration and those of ATD re-administration and the incidence

G-CSF administration for agranulocytosis are yet unclear11,12,13,14. We conducted a long-term retrospective cohort study using data from an administrative claims database in Japan and

examined the quantitative risk and characteristics of ATD-associated leukopenia and G-CSF administration. MATERIALS AND METHODS STUDY DESIGN The data were provided by DeSC Healthcare Inc.

(Tokyo, Japan), and the database comprised claims data of 3.44 million insurance subscribers. The constitution of the database population is reportedly similar to that of the entire

population of Japan, and the database can be used for representative medical epidemiology15. The claims data included the patients’ personal identifiers, date of birth, sex, date of records,

medical diagnoses according to International Classification of Diseases, 10th Revision (ICD-10) codes, medications prescribed, medical procedures, and surgery. These data were anonymously

processed when provided. All patient’s data are anonymized with unique ID codes and can be tracked even if patients are transferred to a different hospital, as long as they do not change

their health insurance. ETHICS This study was conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the Ministry of

Health, Labour and Welfare in Japan. This retrospective cohort study was approved by the Ethics Review Committee of Nara Medical University (approval number: 1123-6). The Ethics Committee of

Nara Medical University waived the requirement for informed consent because all data were anonymized and deidentifed. OUTCOME Patients with GD who were insured in the DeSC Healthcare Inc.

database and received a new ATD prescription (MMI or propylthiouracil, PTU) between October 2014 and February 2021 were included in the analysis. Patients with unknown age, sex, or

observation period were excluded. Patients under 18 years old were excluded because the side effect profiles of antithyroid drugs may differ between children and adults16. To evaluate

patients newly diagnosed with GD, patients who were prescribed an ATD during the 6 months (washout period; April–September 2014) before the observation period were excluded. To increase the

accuracy of the number of G-CSF administrations for ATD-associated agranulocytosis, we first listed all patients who were prescribed G-CSF during the observation period and analyzed the

disease names (13,452 patients, Supplementary Table 1), exhibiting that non-Hodgkin lymphoma, lung cancer and breast cancer were the most common. Therefore, GD patients diagnosed with

lymphoma /leukemia, lung cancer, or breast cancer (n = 276) were excluded from the analysis. These procedures increased the specificity of ATD-associated G-CSF administration. GD diagnosis

was individuals with a diagnosis code indicating GD and those who were prescribed an ATD (MMI or PTU) at least once during the observation period. The administrative claims data do not

include laboratory values such as white blood cell and neutrophil counts. Therefore, leukopenia was defined as presence of a disease code associated with leukopenia or agranulocytosis as per

the ICD-10 code17 as follows; leukopenia, neutropenia, febrile neutropenia, idiopathic neutropenia, granulocyte depletion, drug-induced granulocytes, agranulocytosis, pancytopenia, and

aplastic anemia (Supplementary Table 2) after the initial prescription of an ATD. Additionally, it has been reported that approximately 10% of untreated patients with GD showed a leukocyte

count of less than 4000/μL18, we excluded patients diagnosed with leukopenia before or on the day of the first ATD administration. To validate the significance of leukopenia, patients who

had been administrated G-CSF (filgrastim, lenograstim, or pegfilgrastim) at least once in the ATD-related leukopenia group) were considered to have a severe form of leukopenia. Age was

defined as the age when ATD was first prescribed. The observation period for each patient was defined as from the first ATD prescription date to the earliest of the following dates: the date

of diagnosis of leukopenia or G-CSF administration, the final ATD prescription date + 90 days, the insurance disqualification date, or the end of the observation period. The observation

period for re-administration cases was defined as the number of days since starting the current ATD. For patients who had previously taken both MMI and PTU, the drug (MMI or PTU)

administered immediately before the first occurrence of leukopenia or G-CSF administration was defined. According to the guidelines for treating Graves’ disease in Japan, the starting dose

of MMI is 15 mg for mild to moderate disease, and for severe disease, it was previously 30 mg but is now MMI 15 mg in combination with potassium iodide4. Therefore, we defined MMI≦15 mg as

low-dose and MMI > 15 mg as high-dose. When comparing acute onset and late onset of leukopenia and G-CSF administration, the intersection of two linear regression curves with different

slopes of cumulative incidence in each Kaplan–Meier curve was determined using an approximation formula. The times of acute and late onset were determined at that inflection point.

STATISTICAL ANALYSIS The χ2 test was used for statistical analysis of independence and comparison of frequencies for Fig. 1, sex of Tables 1 and 2. When expected values < 5 were included

in the table, Fisher’s exact probability test was used instead of the χ2 test. The Mann–Whitney U test was used to compare age. The risk ratios (RRs) for the low-dose and high-dose MMI

groups and were calculated by dividing the high-dose incidence by the low-dose incidence. The log-rank test was performed to compare the cumulative incidence between the two groups. Missing

data were excluded on the basis of the study design. SPSS (IBM SPSS Statistics 28.0.1) was used for all the statistical analyses. Statistical significance was defined as _P_ < 0.05.

RESULTS INCIDENCE OF ATD-INDUCED LEUKOPENIA AND G-CSF ADMINISTRATION In total, 14,751 patients with GD were initially recruited for this study during the observation period. Of these, 1800

patients were not newly diagnosed, the observation period was unknown in 8 patients, 176 patients were under 18 years old, and 276 patients had a diagnosis of lung cancer, breast cancer,

lymphoma, or leukemia. Ultimately, the data of 12,491 patients were analyzed (Supplementary Fig. 1). The median observation period was 754 days, approximately 25 months (range, 1–2341 days,

1–78 months). There were 168 patients with ATD-induced leukopenia (1.3%), 38 of whom were administrated G-CSF (22.6%), during the observation period. The median ages (95%CI) of all patients,

patients with leukopenia, patients with G-CSF administration, and patients without G-CSF administration but with leukopenia were 58.0 (55.5–56.1), 57.0 (51.8–56.4), 60.0 (52.4–61.8), and

53.0 (50.5–55.9) years, respectively. Age tended to be older in patients with G-CSF administration than in those without G-CSF administration in patients with leukopenia, although there was

no significant difference (_P_ = 0.24). The sex ratio (female vs male) was 3.0 vs. 1.0, 2.7 vs. 1.0, 2.5 vs. 1.0, and 2.8 vs. 1.0 for all patients, patients with leukopenia, patients with

G-CSF administration, and patients without G-CSF administration but with leukopenia, respectively. There were no significant differences in sex between patients with and without leukopenia

(_P_ = 0.60), as well as in patients with G-CSF administration and those without G-CSF administration but with leukopenia (_P_ = 0.84) (Table 1). The drug names of G-CSF (n = 38) were

filgrastim 30 (79.0%), lenograstim 7 (18.4%), and pegfilgrastim 1 (2.6%) (Supplementary Table 3). ATD DOSE AT THE TIME OF LEUKOPENIA AND G-CSF ADMINISTRATION Among 168 patients with

leukopenia, MMI was prescribed in 153 (91.1%) and the mean dose at the diagnosis of leukopenia was 13.5 mg (95% CI 12.1–15.0 mg). Fifteen patients were treated with PTU, and the mean dose at

the time of diagnosis of leukopenia was 150.0 mg (95% CI 99.8–200.2 mg). Of the 38 patients with G-CSF administration, 35 (92.1%) were prescribed MMI, and the mean dose at G-CSF

administration was 13.6 mg (95% CI 9.5–17.6 mg). Three patients were treated with PTU, and the mean dose at G-CSF administration was 100.0 mg (95% CI 100–100 mg). MAXIMUM ATD DOSE IN

PATIENTS WITH LEUKOPENIA AND G-CSF ADMINISTRATION Of the 12,491 patients, MMI was prescribed in 10,671 (85.4%), PTU was prescribed in 1280 (10.3%), and both MMI and PTU were prescribed in

540 (4.3%) during the observation period. In terms of the dose, 9195 patients (70.5%) were treated with low-dose MMI (≤ 15 mg) and 2016 (15.5%) were treated with high-dose MMI (> 15 mg),

with mean doses of 8.7 mg and 28.3 mg, respectively. In the PTU group, 1223 patients (9.4%) were treated with low-dose PTU (≤ 150 mg), and 597 (4.6%) were treated with high-dose PTU (> 

150 mg), with mean doses of 91.4 mg and 301.3 mg, respectively. The proportions of patients with ATD-induced leukopenia were comparable between the MMI and PTU groups (1.4% vs. 1.8%. _P_ = 

0.17) (Fig. 1). In patients with MMI, the incidence of leukopenia was significantly higher in patients receiving high-dose MMI than in those receiving low-dose MMI (RR 2.9, 95% CI 2.1–4.0

_P_ < 0.01). In patients with PTU, the incidence of leukopenia tended to be higher in patients receiving high-dose PTU than in those receiving low-dose PTU (_P_ = 0.06). The proportions

of patients with G-CSF administration were also comparable between the MMI and PTU groups (0.3% vs. 0.2%. _P_ = 0.36). In patients with MMI, the incidence of G-CSF administration was also

significantly higher in patients receiving high-dose MMI than in those receiving low-dose MMI (RR 2.6, 95% CI 1.3–5.1, _P_ < 0.01). Although the incidence of G-CSF administration in

patients receiving high-dose PTU was lower than that in patients receiving low-dose PTU, there was no significant difference (_P_ = 0.56). CUMULATIVE INCIDENCE OF ATD-INDUCED LEUKOPENIA AND

G-CSF ADMINISTRATION FOR 6 YEARS The Kaplan–Meier curve of the time course and the cumulative incidence of leukopenia in the patients with a first ATD administration are shown in Fig. 2A,

and B shows a magnified view of a portion of Fig. 2A. The incidence of leukopenia during the entire observation period was 5.9 per 1000 person-years. We determined the intersections of two

linear regression curves with different slopes of cumulative incidence in the Kaplan–Meier curves in Fig. 2A and C using an approximation formula, and found the bending point on day 72.

Consequently, we defined the acute-onset group as those with onset on or before day 72 and the late-onset group as those with onset thereafter. The incidence in these two groups was then

calculated. Interestingly, there were clear differences in the incidence of leukopenia between the first 72 days after ATD initiation (acute onset) and the 6-year follow up period (late

onset) (Fig. 2A,B). The incidence of leukopenia in the acute onset group was 37.2 per 1000 person-years (0.7% during the first 72 days), and that in the late onset group was 3.1 per 1000

person-years (Fig. 2B). The incidence of G-CSF administration in patients diagnosed with leukopenia after ATD treatment during the entire observation period was 1.3 per 1000 person-years

(Fig. 2C). Figure 2D shows a magnified view of a portion of Fig. 2C. The same tendency was observed for leukopenia; therefore, we calculated the incidence of leukopenia in the acute and late

phases separately (Fig. 2D). The incidence of G-CSF administration for agranulocytosis in the acute onset group was 8.0 per 1000 person years (0.2% during the first 72 days), and that in

the late onset group was 0.7 per 1000 person-years (Fig. 2D). These data clearly show that there was more than a tenfold difference in the incidence of leukopenia between the acute onset and

late onset groups. Additionally, although the incidence was relatively low, the risk persisted for up to 6 years. COMPARISON OF CLINICAL CHARACTERISTICS BETWEEN THE ACUTE- AND LATE-ONSET

GROUPS The clinical characteristics of patients with ATD-induced leukopenia and G-CSF administration were compared between the acute onset (during the first 72 days) and late onset groups

(during the subsequent 6 years), as determined from the Kaplan–Meier curves in Fig. 2A. (Table 2). There were no significant differences in age, sex, and maximum PTU dose between the acute

onset and late onset groups. Interestingly, for both leukopenia and G-CSF administration, the acute onset group showed a significantly higher maximum dose of MMI than the late onset group

(_P_ < 0.01, _P_ < 0.05, respectively). COMPARISON OF INITIAL MMI DOSE AND MMI DOSE AT G-CSF ADMINISTRATION Comparing the initial MMI dose and the MMI dose of G-CSF administration in

patients treated with MMI, most patients in the acute onset group were treated with 15 mg of MMI, and the dose remained unchanged (Fig. 3). Similarly, most patients in the late onset group

were treated with 5 mg of MMI, and the dose remained unchanged. CUMULATIVE INCIDENCE OF LEUKOPENIA AND G-CSF ADMINISTRATION WITH ATD RE-ADMINISTRATION We further evaluated the incidence of

leukopenia (Fig. 2E) and G-CSF administration (Fig. 2E) in patients who underwent ATD re-administration (Table 3). Among the 12,491 patients treated with ATD, ATD was re-administered in 1528

during the observation period. Among these, 14 exhibited leukopenia and 3 were treated with G-CSF (Table 3). The median discontinuation period of ATD was 299 days (range, 171–1240 days).

Among 14 patients, 10 developed leukopenia rapidly during the first 62 days after the initiation of re-administration (Table 3, Cases 1–10, 35 days [range, 16–62 days]), and 4 developed

leukopenia slowly during the subsequent days (Table 3, Cases 11–14, 346 days [range, 155–646 days]). Interestingly, the Kaplan–Meier curve of the cumulative incidence of leukopenia and G-CSF

administration in patients with re-administration revealed a similar shape to that of the first administration, although the patient number was small in G-CSF administration group (Fig. 

2E,F). We calculated the incidence of acute onset (the first 62 days) and late onset (the subsequent days up to 2 years). The incidence of leukopenia in the acute onset group was 41.1 per

1000 person-years (0.7% during the first 62 days), and that in the late onset group was 3.4 per 1000 person-years (Fig. 2E). The incidence of G-CSF administration for leukopenia in the acute

onset group was 8.2 per 1000 person-years (0.1% during the 62 days), and that in the late onset group was 0.9 per 1000 person-years (Fig. 2F). Comparison of the Kaplan–Meier curves of the

cumulative incidence of leukopenia and G-CSF administration between the first administration and re-administration showed no significant differences (log-rank test, _P_ = 0.63, _P_ = 0.85,

respectively), indicating that the risk of leukopenia and G-CSF administration was similar. DISCUSSION In this study, we clearly demonstrated that the risk of ATD-induced leukopenia and

G-CSF administration was biphasic; its incidence in the acute onset group was 37.2 per 1000 person-years (0.7% during the first 72 days) and that in the late onset group was 3.1 per 1000

person-years, which was 10 times lower than that in acute onset group, with the risk persisting for at least for 6 years. The risk of G-CSF treatment generally administered for management of

severe leukopenia in the acute group was 8.0 per 1000 person-years (0.2% during the first 72 days) and that in the late onset group was 0.7 per 1000 person-years. In addition, the risk of

leukopenia and G-CSF administration was similar between first ATD administration and ATD re-administration. ATD treatment for GD is generally provided in outpatient clinics. It is a standard

therapy, and ATD has been used to treat GD in more than 90% of patients in Japan19,20, 85% of patients in Europe21, and more than 40% of patients in the US, where ATD use has been

increasing and RAI use has been decreasing3. Guidelines recommend ATD, particularly MMI, as the initial therapy for GD, and patients are generally treated with ATD for 12–18 months1,5,22. In

addition, long-term treatment with low-dose MMI for a total of 60–120 months may also be efficacious, with higher remission rates than those observed with the conventional 18–24 months

course2,23. Indeed, in real clinical practice, it is not rare to prescribe ATD for a long period; therefore, it is necessary to keep in mind the precise risk of leukopenia and G-CSF

administration with long-term treatment. Based on our data, we recommend focusing on this risk in a long term treatment, although the incidence is low. A previous report has shown that

elderly patients are susceptible to agranulocytosis5. In this study, we demonstrated that there was a tendency for patients with G-CSF administration to be older. Additionally, there are

reports showing that women have a higher risk of developing agranulocytosis3,5,8, but there were no significant differences in sex between patients with G-CSF administration and ATD-treated

patients in this study. The reported incidence of agranulocytosis due to MMI and PTU remains controversial; it has been reported that the incidence is significantly higher for PTU than for

MMI24, although another study found no difference25. In this study, there were no significant differences in leukopenia and G-CSF administration between the PTU and MMI groups. However, PTU

was prescribed in only 14.6% of the patients in this study, and the relatively small number of patients receiving PTU may influence the results. In terms of the ATD dose, it is reported that

the risk of MMI-induced agranulocytosis is higher with an initial dose of 30 mg/d than with a dose of 15 mg/d26. In this study, the incidence of leukopenia and G-CSF administration was

significantly higher in patients treated with more than 15 mg of MMI than in those treated with 15 mg or less of MMI (RR 2.9 and 2.6,, respectively), supporting previously reported

results26. The incidence of leukopenia tended to be higher in patients treated with more than 150 mg of PTU than in those treated with 150 mg or less pf PTU (_P_ = 0.06). The incidence of

G-CSF administration was lower in patients receiving high-dose PTU than in those receiving low-dose PTU. However, this difference was not statistically significant (_P_ = 0.56), and the

relatively small number of patients receiving high-dose PTU (n = 597) may have influenced the results. Interestingly, there was a biphasic risk of leukopenia and G-CSF administration during

ATD treatment. Although the detailed mechanisms remain unclear, two mechanisms have been proposed: direct ATD toxicity and immune-mediated responses27,28,29. Reactive metabolites produced

during ATD oxidization in neutrophils may exert direct toxicity18. Autoantibodies against mature blood cells and/or bone precursor cells are involved in immune-mediated responses29,30,31. We

postulated that the different incidences of agranulocytosis in the acute and late phases may be explained by these different mechanisms. There are limited data on the risk of

agranulocytosis with ATD re-administration. In a previous study, the clinical characteristics between the first administration and re-administration groups were comparable, including the

period after ATD administration and agranulocytosis diagnosis (39.0 days vs. 32.5 days)32. In this study, although the patient number of administered G-CSF in the re-administration group was

limited; therefore, caution is required when interpreting the findings in G-CSF administration group, but the incidence of leukopenia and G-CSF administration was similar between the first

administration and re-administration of ATD. Moreover, we clearly showed that the risk was biphasic in leukopenia group, similar to the first administration. Therefore, it is recommended

that similar attention be paid when an ATD is re-administered. Our study has several limitations and strength. It is important to acknowledge a limitation of this study, notably that due to

the characteristics of the administrative claims database, laboratory findings such as thyroid hormone levels and thyroid function index33 were not available. Therefore, the appropriateness

of antithyroid medication, dosage, and duration of administration cannot be examined. However, since the purpose of this study was to clarify antithyroid drug-related leukopenia and G-CSF

administration, we believe that these limitations do not affect the conclusions. Furthermore, agranulocytosis is generally defined as granulocyte count of less than 500/μL; however, the

definition of leukopenia in this study cannot exclude the mild leukocytopenia that does not meet the criteria of agranulocytosis. However, we defined not only by leukopenia but also by G-CSF

administration, which is generally used for severe leukocytopenia. In addition, patients administered G-CSF for other purposes, such as chemotherapy, were carefully excluded. As a result,

the data on leukopenia and G-CSF administration were consistent, suggesting the integrity of this study. Second, we set a wash out period of 6 months for the definition of newly prescribed

ATD; therefore, it is difficult to exclude the patients who prescribed ATD more than 6 months before. Third, there is a possibility of underestimating the incidence of leukopenia and G-CSF

administration related to ATD because we excluded patients with three malignancies for which G-CSF commonly used, and some of these patients had both ATD and G-CSF treatment. However, the

incidence of G-CSF administration with these malignancies was 1.7% (276/16,596); therefore, their influence was negligible and we believe that it did not affect the conclusion. As a

strength, this study included a relatively large number of patients with GD who were prescribed ATD, and the observation period was sufficiently long, compared with those of previous

studies6,23, to enable quantification of long-term risk. Furthermore, the selection bias was small, reflecting real world clinical practice. In conclusion, the risk of ATD-induced leukopenia

and G-CSF administration was biphasic. A high incidence was observed in the first 72 days following the initiation of treatment, and a reduced risk was observed for at least the subsequent

6 years. The incidence was similar in the case of re-administration. ATD is a standard therapy and is often administered for a long period; therefore, our findings can guide treatment for

GD. DATA AVAILABILITY The data that support the findings of this study are available from DeSC Healthcare Inc. (Tokyo, Japan) but restrictions apply to the availability of these data, which

were used under license for the current study, and so are not publicly available. Data are however available from the corresponding author upon reasonable request and with permission of DeSC

Healthcare Inc. (Tokyo, Japan). REFERENCES * Kahaly, G. J. _et al._ 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. _Eur. Thyroid J._ 7, 167–186.

https://doi.org/10.1159/000490384 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  * Azizi, F. _et al._ Increased remission rates after long-term methimazole therapy in patients

with Graves’ disease: Results of a randomized clinical trial. _Thyroid_ 29, 1192–1200. https://doi.org/10.1089/thy.2019.0180 (2019). Article  CAS  PubMed  Google Scholar  * Ross, D. S. _et

al._ 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. _Thyroid_ 26, 1343–1421.

https://doi.org/10.1089/thy.2016.0229 (2016). Article  PubMed  Google Scholar  * Guideline for the Tratment of Graves’ Disease in Japan. Japan Thyroid Association, 2019.

https:perperwww.japanthyroid.jpperdoctorperguidelineperindex.html. * Burch, H. B. & Cooper, D. S. Management of Graves disease: A review. _J. Am. Med. Assoc._ 314, 2544–2554.

https://doi.org/10.1001/jama.2015.16535 (2015). Article  CAS  Google Scholar  * Watanabe, N. _et al._ Antithyroid drug-induced hematopoietic damage: A retrospective cohort study of

agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. _J. Clin. Endocrinol. Metab._ 97, E49–E53. https://doi.org/10.1210/jc.2011-2221 (2012). Article  CAS  PubMed

  Google Scholar  * Nakamura, H., Miyauchi, A., Miyawaki, N. & Imagawa, J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. _J. Clin. Endocrinol.

Metab._ 98, 4776–4783. https://doi.org/10.1210/jc.2013-2569 (2013). Article  CAS  PubMed  Google Scholar  * Yang, J. _et al._ Characteristics of antithyroid drug-induced agranulocytosis in

patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. _Thyroid_

26(5), 627–633 (2016). Article  CAS  PubMed  Google Scholar  * Stellingwerf, M., Jellema, W. T., Eland, I. A. & Wakelkamp, I. M. Agranulocytosis/granulocytopenia after long-term use of

thiamazole. _Ned Tijdschr Geneeskd_ 155, A2430 (2011). PubMed  Google Scholar  * Mutharasan, P., Oatis, W., Kwaan, H. & Molitch, M. Delayed anithyroid drug-induced agranulocytosis.

_Endocrine Pract._ 18, e69–e72. https://doi.org/10.4158/EP11339.CR (2012). Article  Google Scholar  * Andres, E. _et al._ Haematopoietic growth factor in antithyroid-drug-induced

agranulocytosis. _QJM Int. J. Med._ 94, 423–428. https://doi.org/10.1093/qjmed/94.8.423 (2001). Article  CAS  Google Scholar  * Tajiri, J. & Noguchi, S. Antithyroid drug-induced

agranulocytosis: How has granulocyte colony-stimulating factor changed therapy?. _Thyroid_ 15, 292–297. https://doi.org/10.1089/thy.2005.15.292 (2005). Article  CAS  PubMed  Google Scholar 

* Fukata, S., Kuma, K. & Sugawara, M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: A prospective study.

_Thyroid_ 9, 29–31. https://doi.org/10.1089/thy.1999.9.29 (1999). Article  CAS  PubMed  Google Scholar  * Wang, Y. _et al._ Granulocyte-colony-stimulating factor effectively shortens

recovery duration in anti-thyroid-drug-induced agranulocytosis: A systematic review and meta-analysis. _Front. Endocrinol. (Lausanne)_ 10, 789. https://doi.org/10.3389/fendo.2019.00789

(2019). Article  PubMed  Google Scholar  * Okada, A. & Yasunaga, H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young,

middle-aged, and elderly people. _JMA J._ 5, 190–198. https://doi.org/10.31662/jmaj.2021-0189 (2022). Article  PubMed  PubMed Central  Google Scholar  * Rivkees, S. A. & Mattison, D. R.

Ending propylthiouracil-induced liver failure in children. _N. Engl. J. Med._ 360(15), 1574–1575. https://doi.org/10.1056/NEJMc0809750 (2009). Article  CAS  PubMed  Google Scholar  *

Sebastian, K., Rene, P., Inke, R. K., Roland, L. & Markus, S. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data.

_Naunyn-Schmiedeberg’s Arch. Pharmacol._ 393, 681–690 (2020). Article  Google Scholar  * Roti, E. _et al._ Effects of chronic iodine administration on thyroid status in euthyroid subjects

previously treated with antithyroid drugs for Graves’ hyperthyroidosm. _J. Clin. Endocrinol. Metab._ 77, 928–932 (1993). Google Scholar  * Lam, D. C. & Lindsay, R. H. Accumulation of

2-[14C]propylthiouracil in human polymorphonuclear leukocytes. _Biochem. Pharmacol._ 28, 2289–2296. https://doi.org/10.1016/0006-2952(79)90692-0 (1979). Article  CAS  PubMed  Google Scholar

  * Tamai, H. _et al._ Methimazole-induced agranulocytosis in Japanese patients with Graves’ disease. _Clin. Endocrinol._ 30, 525–530. https://doi.org/10.1111/j.1365-2265.1989.tb01424.x

(1989). Article  CAS  Google Scholar  * Burch, H. B., Burman, K. D. & Cooper, D. S. A 2011 survey of clinical practice patterns in the management of Graves’ disease. _J. Clin.

Endocrinol. Metab._ 97, 4549–4558. https://doi.org/10.1210/jc.2012-2802 (2012). Article  CAS  PubMed  Google Scholar  * Cooper, D. S. Antithyroid drugs in the management of patients with

Graves’ disease: An evidence-based approach to therapeutic controversies. _J. Clin. Endocrinol. Metab._ 88, 3474–3481. https://doi.org/10.1210/jc.2003-030185 (2003). Article  CAS  PubMed 

Google Scholar  * Azizi, F. Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. _Thyroid_ 30, 1451–1457.

https://doi.org/10.1089/thy.2019.0814 (2020). Article  CAS  PubMed  Google Scholar  * Pearce, S. H. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK.

_Clin. Endocrinol._ 61, 589–594. https://doi.org/10.1111/j.1365-2265.2004.02135.x (2004). Article  Google Scholar  * Tajiri, J. & Noguchi, S. Antithyroid drug-induced agranulocytosis:

Special reference to normal white blood cell count agranulocytosis. _Thyroid_ 14, 459–462. https://doi.org/10.1089/105072504323150787 (2004). Article  CAS  PubMed  Google Scholar  * Takata,

K. _et al._ Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. _Thyroid_ 19, 559–563.

https://doi.org/10.1089/thy.2008.0364 (2009). Article  CAS  PubMed  Google Scholar  * Vicente, N., Cardoso, L., Barros, L. & Carrilho, F. Antithyroid drug-induced agranulocytosis: State

of the art on diagnosis and management. _Drugs R&D_ 17, 91–96. https://doi.org/10.1007/s40268-017-0172-1 (2017). Article  CAS  Google Scholar  * Johnston, A. & Uetrecht, J. Current

understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. _Expert Opin. Drug Metab. Toxicol._ 11, 243–257. https://doi.org/10.1517/17425255.2015.985649 (2015). Article 

CAS  PubMed  Google Scholar  * Kaplan, S. H., Greenfield, S., Gandek, B., Rogers, W. H. & Ware, J. E. Jr. Association between the DRB1*08032 histocompatibility antigen and

methimazole-induced agranulocytosis in Japanese patients with Graves disease. _Ann. Intern. Med._ 124, 490–494. https://doi.org/10.7326/0003-4819-124-5-199603010-00005 (1996). Article 

Google Scholar  * Fibbe, W. E. _et al._ Agranulocytosis induced by propylthiouracil: Evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor

cells. _Br. J. Haematol._ 64, 363–373. https://doi.org/10.1111/j.1365-2141.1986.tb04130.x (1986). Article  CAS  PubMed  Google Scholar  * Douer, D. & Eisenstein, Z. Methimazole-induced

agranulocytosis: Growth inhibition of myeloid progenitor cells by the patient’s serum. _Eur. J. Haematol._ 40, 91–94. https://doi.org/10.1111/j.1600-0609.1988.tb00803.x (1988). Article  CAS

  PubMed  Google Scholar  * Kobayashi, S. _et al._ Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. _Thyroid_ 24,

796–801. https://doi.org/10.1089/thy.2013.0476 (2014). Article  CAS  PubMed  Google Scholar  * Chu, Y. D. _et al._ A novel thyroid function index associated with opposite therapeutic

outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib. _Asia Pac. J. Clin. Oncol._ 14(5), e341–e351 (2018). Article  PubMed  Google Scholar  Download

references ACKNOWLEDGEMENTS The DeSC database was provided by DeSC Healthcare, Inc. under their academic research support program. FUNDING This study was supported by Grants-in-Aid for

Scientific Research (21K10474 to FK, 22H03355 to YN, and 21K10451 to SO), the Ministry of Health, Labor and Welfare (Hypothalamo-hypophyseal Disorders and Endocrine Syndrome with Sexual

Differentiation and Maturation grant to YT), and Nara Medical University Center for Diversity and Inclusion (grant to FK). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of

Diabetes and Endocrinology, Nara Medical University, 840, Shijo-Cho, Kashihara, Nara, 634-8522, Japan Fumika Kamitani, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada &

 Yutaka Takahashi * Department of Public Health, Health Management and Policy, Nara Medical University, 840, Shijo-Cho, Kashihara, Nara, 634-8521, Japan Yuichi Nishioka, Shinichiro Kubo, 

Tomoya Myojin, Tatsuya Noda & Tomoaki Imamura Authors * Fumika Kamitani View author publications You can also search for this author inPubMed Google Scholar * Yuichi Nishioka View author

publications You can also search for this author inPubMed Google Scholar * Miyuki Koizumi View author publications You can also search for this author inPubMed Google Scholar * Hiroki

Nakajima View author publications You can also search for this author inPubMed Google Scholar * Yukako Kurematsu View author publications You can also search for this author inPubMed Google

Scholar * Sadanori Okada View author publications You can also search for this author inPubMed Google Scholar * Shinichiro Kubo View author publications You can also search for this author

inPubMed Google Scholar * Tomoya Myojin View author publications You can also search for this author inPubMed Google Scholar * Tatsuya Noda View author publications You can also search for

this author inPubMed Google Scholar * Tomoaki Imamura View author publications You can also search for this author inPubMed Google Scholar * Yutaka Takahashi View author publications You can

also search for this author inPubMed Google Scholar CONTRIBUTIONS Conception and design: F.K., Y.N., Y.T. Analysis and interpretation of the data: F.K., Y.N., Y.T. Drafting of the article:

F.K., Y.T. Critical revision for important intellectual content: F.K., Y.N., Y.T. Final approval of the article: F.K., Y.N., M.K., H.N., Y.K., S.O., S.K., T.M., T.N., T.I., Y.T. Statistical

expertise: Y.N., T.N., T.I. Administrative, technical, or logistic support: Y.N., T.M., S.K. Collection and assembly of data: F.K., Y.N. CORRESPONDING AUTHOR Correspondence to Yuichi

Nishioka. ETHICS DECLARATIONS COMPETING INTERESTS FK received speaker fees from Dainippon Sumitomo, Sanofi, and Kyowa Kirin. YN received consultation fees from Novo Nordisk. SO received

speaker fees from Ono; Mitsubishi Tanabe; Dainippon Sumitomo; Eli Lilly, Japan; Takeda; AstraZeneca; Novartis Pharmaceuticals; Novo Nordisk; Mochida Pharmaceutical; Kyowa Kirin; and Terumo.

YT received consultant fees from Novo Nordisk, Otsuka, and Recordati and speaker fees from Novo Nordisk, Sumitomo Dainippon, Eli Lilly, Ono, Novartis, Nippon Boehringer Ingelheim,

AstraZeneca, and Kyowa Kirin. The other authors declare that they have no conflicts of interest. ADDITIONAL INFORMATION PUBLISHER'S NOTE Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURE 1. SUPPLEMENTARY INFORMATION. RIGHTS AND PERMISSIONS OPEN ACCESS This

article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as

you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party

material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the

article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the

copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kamitani, F., Nishioka, Y.,

Koizumi, M. _et al._ Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study. _Sci Rep_ 13, 19336 (2023). https://doi.org/10.1038/s41598-023-46307-5 Download

citation * Received: 19 December 2022 * Accepted: 30 October 2023 * Published: 07 November 2023 * DOI: https://doi.org/10.1038/s41598-023-46307-5 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative